Sugi Predict

Sugi Predict / Compounds / SCHEMBL302530

SCHEMBL302530

SCHEMBL302530

O=Cc1cccc(-c2ccncc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRIM24 O15164 1/20 0.56
▸ TRIM33 Q9UPN9 1/20 0.56
▸ CA12 O43570 1/20 0.54
▸ CA1 P00915 1/20 0.54
▸ CA2 P00918 1/20 0.54
▸ CA9 Q16790 1/20 0.54
▸ ERN1 O75460 1/20 0.49
▸ NOTUM Q6P988 1/20 0.48
▸ PRKCI P41743 1/20 0.47
▸ KIF11 P52732 1/20 0.47
▸ CDK8 P49336 1/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ CHEK1 O14757 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ ROCK2 O75116 1/20 0.43
▸ ROCK1 Q13464 1/20 0.43
▸ PRMT6 Q96LA8 1/20 0.43
▸ AXL P30530 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29534997 1.00 TRIM24 (0.56) TRIM24TRIM33CA12CA1CA2
SCHEMBL27621710 0.87 TRIM24 (0.68) TRIM24TRIM33CA12CA1CA2
SCHEMBL11770226 0.85 TRIM24 (0.71) TRIM24TRIM33CA12CA1CA2
SCHEMBL346974 0.85 TRIM24 (0.64) TRIM24TRIM33CA12CA1CA2
SCHEMBL29414645 0.83 TRIM24 (0.69) TRIM24TRIM33CA12CA1CA2
SCHEMBL97618 0.83 TRIM24 (0.69) TRIM24TRIM33CA12CA1CA2
SCHEMBL29163629 0.81 MAPT (0.50) ERN1NOTUMKIF11CDK8ALDH1A1
SCHEMBL28460866 0.81 TRIM24 (0.67) TRIM24TRIM33CA12CA1CA2
SCHEMBL5916092 0.81 TRIM24 (0.67) TRIM24TRIM33CA12CA1CA2
SCHEMBL29700451 0.81 TRIM24 (0.67) TRIM24TRIM33CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130225825-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-08-29 — — US claimed
JP-4851440-B2 — — 2012-01-11 — — JP claimed
EP-1723140-B1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS AVENTIS PHARMA INC (US) 2009-11-04 — — EP claimed
CN-101429194-A Process for the preparation of tryptase inhibitors AVENTIS PHARMA INC (US) 2009-05-13 — — CN claimed
CN-100343256-C Biaryl substituted diazabicycloalkane amides as nicotinic acetylcholine agonists ASTRAZENECA AB (SE) 2007-10-17 — — CN claimed
US-20070197597-A1 Process for the preparation of tryptase inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 — — US claimed
CN-1950362-A Preparation method of tryptase inhibitor AVENTIS PHARMA INC (US) 2007-04-18 — — CN claimed
EP-1723140-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-11-22 — — EP claimed
WO-2005095385-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-10-13 — — WO claimed
CN-1678615-A Biaryl substituted diazabicycloalkanes as nicotinic acetylcholine antagonists ASTRAZENECA AB (SE) 2005-10-05 — — CN claimed
EP-1571150-A1 Process for the preparation of tryptase inhibitors Aventis Pharma Deutschland GmbH (DE) 2005-09-07 — — EP claimed
CN-119552120-A Pyrazole and imidazole compounds for inhibiting IL-17 and rory 里亚塔医药公司 2025-03-04 — — CN disclosed
CN-112654610-B Pyrazole and imidazole compounds for inhibiting IL-17 and rory 里亚塔医药公司 2024-12-24 — — CN disclosed
US-20240360084-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA REATA PHARMACEUTICALS INC (US) 2024-10-31 — — US disclosed
US-11993574-B2 Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma REATA PHARMACEUTICALS, INC (US) 2024-05-28 — — US disclosed
EP-0937078-B1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXOSMITHKLINE SPA (IT) 2003-02-12 — — EP disclosed
US-20010047094-A1 Tricyclic carbapenem compounds GLAXO WELLCOME SPA 2001-11-29 — — US disclosed
CN-1242773-A Ticyclic carbapenem compound GLAXO WELLCOME SPA (IT) 2000-01-26 — — CN disclosed
EP-0937078-A1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXO WELLCOME S.p.A. (IT) 1999-08-25 — — EP disclosed
WO-1998021210-A1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXO WELLCOME S.P.A. (IT) 1998-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225825-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS CMA1, TPSAB1, TPSB2 TRIM24 2757/4885TRIM33 4033/4885CA12 1599/4885
US-20010047094-A1 Tricyclic carbapenem compounds OXA1L, GNE, MGAM TRIM24 1323/4885TRIM33 1505/4885CA12 2822/4885
US-20240360084-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA RORC, RORB, RORA TRIM24 806/4885TRIM33 2681/4885CA12 2875/4885
US-11993574-B2 Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma RORC, RORB, RORA TRIM24 806/4885TRIM33 2681/4885CA12 2875/4885
US-20070197597-A1 Process for the preparation of tryptase inhibitors CMA1, TPSAB1, TPSB2 TRIM24 2757/4885TRIM33 4033/4885CA12 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.